Citations

Clear

705 citation(s) found for "Cooper, C B".

Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Practice Patterns in Management of Low‐ to Intermediate‐Grade Salivary Gland Carcinoma: A Multi‐Institutional Study
Sajisevi, Mirabelle , Nguyen, Kenny , Holcomb, Andrew J. , Vural, Emre , Davis, Kyle P. , Thomas, Carissa M. , Stein, John S. , Aulet, Ricardo , Bell, Rebecca K. , Blasco, Michael A., Bowmaster, Vanessa B., Chung, Jeffson , Cognetti, David M. , Cordero, Joehassin , Donovan, John, Du, Yue , Eskander, Antoine , Feinberg, Philip A. , Garvey, Emily A. , Goldstein, David P. , Goulart, Rafael Nunes, Grasl, Stefan , Giurintano, Jonathan , Hara, Jared H. , Hinni, Michael L., Hua, Nadia , Johnson‐Obaseki, Stephanie , Kalman, Noah S. , Khaja, Sobia F. , Ku, Jamie A., Lambert, Arnaud, Luu, Bao K. , Magliocca, Kelly R. , Santos, Luiz Roberto Medina dos , Michael, C. A., Miles, Brett, Melo, Giulianno Molina de , Moore, Michael G. , Moura, Kauê, Noroozi, Hesameddin, Patel, Rusha , Paydarfar, Joseph A. , Plonowska‐Hirschfeld, Karolina A. , Savaria, Fabrice N., Schmitt, Nicole C. , Shapiro, Justin , Stokes, William A. , Sulibhavi, Anita , Vendra, Varun , Vinh, Daniel , Virgen, Celina G. , Woody, N.M. , Young, Geoffrey D., Enepekides, Danny , Hier, Michael , Ryan, William R. , Holcomb, Andrew J , Thomas, Carissa M , Asarkar, Ameya A , Chung, Jeffson , Chan, Kimberly , Chang, Brent A , Dundar, Yusuf , Dedivitis, Rogerio , Goldstein, David , Goyal, Neerav , Grasl, Stefan , Giurintano, Jonathan , Gupta, Nikita , Habib, Andy , Hackman, Trevor , Henson, Christina , Kejner, Alexandra E , de Melo, Giulianno Molina , Morand, Gregoire B , Paydarfar, Joseph , Sadeghi, Nader , Schmitt, Nicole C , Shaver, Timothy B , Tasoulas, Jason , CALLAS, PETER W. , Burruss, Clayton P. , Chang, Brent A. , Coffey, Charles S. , Cooper, Dylan Jacob , Donovan, John, Edwards, Heather , Erović, Boban M. , Goodman, Joseph , Juloori, Aditya , Michael, Cara, Miles, Brett, Morand, Grégoire B. , Stoeckli, Sandro Johannes , Kakarala, Kiran , Davies, Louise

Mayo Clinic

Laryngoscope Investigative Otolaryngology | September 23, 2025 | Volume: 10 | Issue: 5 | Pages: No page available

10.1002/lio2.70246 | PMID 40995062 Get It

ABSTRACT Objectives To characterize practice patterns and outcomes in the management of low‐ and intermediate‐grade salivary gland carcinoma prior to the existence of treatment guidelines. Methods Analysis of a registry of patients who underwent parotid and submandibular gland resections for low‐and intermediate‐grade carcinomas between 2010 and 2019. Results Of all 786 patients included in the study, 726 (92%) had preoperative imaging and 653 (83%) had preoperative biopsy. Of the 729 patients with parotid gland cancer, the majority underwent superficial ( n = 384, 53%) or total ( n = 254, 35%) parotidectomy. In patients with facial nerve preservation, total parotidectomy was associated with a significant increase in transient facial weakness (72/177 (41%) vs. 82/311 (26%), RR 0.65, 95% CI 0.50–0.84, p < 0.05) and permanent facial nerve weakness (23/176 (13%) vs. 16/301 (5%), RR 0.41, 95% CI 0.22–0.75, p < 0.05) compared to superficial parotidectomy. Adjuvant radiation therapy ( RT ) was delivered to 285 (36%) patients. The proportion of patients receiving adjuvant RT declined significantly over the time period from 2015 to 2019 compared to 2010 to 2014 at 162/504 (32%) and 123/282 (44%), respectively ( RR 0.74, 95% CI 0.61–0.89, p < 0.05). When comparing the time periods from 2015 to 2019 and 2010 to 2014, there was no significant difference in local control rates ( RR 0.52, 95% CI 0.26–1.04, p = 0.06) or regional control rates ( RR 0.75, 95% CI 0.26–2.13, p = 0.58). Conclusions Management of low‐ and intermediate‐grade salivary cancer from 2010 to 2019 was variable, which is expected given the rarity and heterogeneity of the disease and the lack of treatment guidelines prior to 2021. Most patients with parotid malignancies underwent superficial or total parotidectomy. The extent of parotidectomy had an impact on facial nerve function outcomes. Delivery of adjuvant radiation trended down with time. The data presented here will support dissemination of the guidelines and provide data that could inform future trials. Level of Evidence 2b.
Community-based participatory design of a decade: the FAITH! Cardiovascular Health and Wellness Program
Lalika, Mathias , Kyalwazi, Ashley, Albertie, Monica, Bowie, Janice , Burgess, Ashya, Elegbede, Walé, Erickson, Jamia, Jenkins, Sarah M. , Johnson, Jacquelyn, Krogman, Ashton , Moen, Lainey , Palmer, Michael W. , Penheiter, Sumedha G., Richard, Monisha, Titus, Princess, Schardin, Sueling, Shanedling, Stanton , Hof, Jeremy Van’t , Weis, Jennifer A., Patten, Christi A. , Penheiter, Sumedha, Warner, David, Weis, Jennifer, Brewer, LaPrincess C. , Burke, Lora E. , Buta, Brian J. , Cooper, Lisa A. , Crews, Deidra C. , Doubeni, Chyke A. , Johnson, Jacquelyn, Jones, Clarence , Palmer, Michael, Warner, David O. , Hayes, Sharonne N.

Mayo Clinic

Frontiers in Public Health | September 23, 2025 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fpubh.2025.1622237 | PMID 41063935 Get It

The FAITH! (Fostering African-American Improvement in Total Health) Cardiovascular Health and Wellness Program is more than a decade-long community-based participatory research initiative aimed at addressing cardiovascular health disparities among African-Americans in Minnesota. Founded in 2013, the program employs a culturally tailored, community-driven approach by partnering with African-American faith communities to promote cardiovascular health through education, digital health tools, and multilevel interventions targeting the social determinants of health. Grounded in community-based participatory research principles, FAITH! prioritizes equitable academic-community partnerships, co-learning, community capacity building, and shared ownership in all aspects of research and implementation. The program’s exemplary innovations include the NIH-funded FAITH! Trial, a randomized clinical trial, testing a mobile health intervention (the FAITH! App) co-created with the African-American community, and the Techquity by FAITH! study. Techquity by FAITH! evaluates the effectiveness of a culturally relevant, community-informed mHealth intervention supported by a Digital Health Advocate network to improve overall cardiovascular health and digital health literacy. During its evolution, FAITH! has addressed emergent public health crises, including the COVID-19 pandemic, by adapting programming to provide emergency preparedness resources, health education, and vaccine outreach. Key outcomes include sustainable church-based health ministries, increased research participation, and successful translation of research into practice. The program has also contributed to research workforce development by mentoring and training diverse early-career scholars and community leaders in community-based participatory research and cardiovascular health equity research. Lessons learned highlight the transformative impact of community-based participatory research in building trust, facilitating culturally relevant dissemination, and sustaining health equity initiatives. The FAITH! model demonstrates a scalable, community-led strategy for advancing cardiovascular health in underserved populations and provides a blueprint for future initiatives aiming to reduce racial health disparities.
Factors associated with early neurological deterioration in minor distal medium vessel acute ischemic stroke: A multinational multicenter study
Lakhani, Dhairya A. , Salim, Hamza , Yedavalli, Vivek , Milhem, Fathi , Adeeb, Nimer , Faizy, Tobias D. , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Rouchaud, Aymeric, Fiehler, Jens, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Abdalkader, Mohamad , Marrota, Thomas, Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza , Griessenaur, Christoph, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Investigators, for the MAD MT, Salim, Hamza , Faizy, Tobias D , Henninger, Nils , Tan, Benjamin Yq , Cancelliere, Nicole M , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Clarençon, Frédéric , Siegler, James E , Nguyen, Thanh N , Essibayi, Muhammed Amir , Gonzalez, Nestor R , Marnat, Gaultier , Pedicelli, Alessandro , Alexandre, Andrea M , Guenego, Adrien , Dmytriw, Adam A , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Regenhardt, Robert W , Lakhani, Dhairya , Yedavalli, Vivek S , Varela, Ricardo , Musmar, Basel , Daraghma, Motaz , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Marotta, Thomas R. , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Essibayi, Muhammed Amir , Costalat, Vincent , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Tancredi, Illario , Mendes Pereira, Vitor , Wintermark, Max , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

International Journal of Stroke | September 16, 2025 | Volume: 21 | Issue: 3 | Pages: 343-352

10.1177/17474930251381946 | PMID 40954523 Get It

Background: Patients with acute ischemic stroke secondary to distal and medium vessel occlusion (AIS-DMVO) and minor strokes present a challenge in determining the most appropriate emergent treatment. Factors leading to early neurological deterioration (END) in this patient population are understudied, but END is known to result in poor functional outcomes. Therefore, we aimed to investigate the factors contributing to END in minor AIS-DMVO cases. Methods: We included patients with AIS-DMVO and minor strokes from 37 sites across North America, Asia, and Europe. Minor stroke was defined as a baseline National Institutes of Health Stroke Scale (NIHSS) score of ⩽5. The primary outcome measure, END, was defined as a shift of ⩾4 points in the NIHSS score at day one after treatment compared to baseline. Univariable and multivariable logistic regression analyses were performed to identify factors associated with END. Results: Among 559 consecutive patients with DMVO and minor strokes, END was reported in 68 patients. In multivariable analysis, mechanical thrombectomy (MT) was independently associated with higher odds of END (adjusted odds ratio [aOR] 2.37, 95% CI 1.12–5.02, p = 0.02), while intravenous thrombolysis (IVT) was associated with lower odds of END (aOR 0.46, 95% CI 0.26–0.81, p = 0.008). However, the association between MT and END was no longer statistically significant in the IPTW-adjusted analysis (OR 1.65, 95% CI 0.69–3.98, p = 0.26). Hypertension and antiplatelet use at baseline were also independently associated with END. Among MT-treated patients, successful and excellent recanalization and first-pass effect were protective against END. Conclusion: MT was associated with END in patients with minor AIS-DMVO, although this association was not significant after IPTW adjustment. IVT was independently associated with reduced risk of END. These findings support careful patient selection and further study in randomized trials.
Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease
Starr, Philip A. , Shivacharan, Rajat S. , Goldberg, E. Matilda, Tröster, Alexander I. , House, P.A. , Giroux, Monique, Hebb, Adam O. , Whiting, Donald, Leichliter, Timothy, Ostrem, Jill L. , Metman, Leo Verhagen , Karl, Jessica , Siddiqui, Mustafa , Haq, Ihtsham , Moguel‐Cobos, Guillermo , Ponce, Francisco A. , Pahwa, Rajesh, Lyons, Kelly , Buetefisch, Cathrin M. , Luca, Corneliu , Jagid, Jonathan , Revuelta, Gonzalo J. , Takács, István , Pourfar, Michael , Mandybur, George, Zadikoff, Cindy , Khandhar, Suketu M., Sedrak, Mark , Phibbs, Fenna T., Neimat, Joseph S. , Durphy, Jennifer, Ramirez‐Zamora, Adolfo , Pilitsis, Julie G. , Uitti, Ryan J. , Wharen, Robert E. , Park, Michael C. , Vitek, Jerrold L. , Group, INTREPID Study, Galifianakis, Nicholas B. , Schrock, Lauren E. , Farris, Sierra, Nazzarro, Jules M., Haq, Ihtsham , Ramirez-Zamora, Adolfo , Goldberg, Edward, Sani, Sepehr , Tatter, Stephen B. , Machado, André G. , Gostkowski, Michał , Tagliati, Michele , Mamelak, Adam N. , Okun, Michael S. , Foote, Kelly D. , Pahwa, Rajesh , Gross, Robert E. , Takacs, Istvan, Mogilner, Alon Y. , Duker, Andrew , Rosenow, Joshua M. , Group, INTREPID Study, Luciano, Marta San , Cooper, Scott E.

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1181

10.1001/jamaneurol.2025.3373 | PMID 40952750 Get It

Importance The Implantable Neurostimulator for the Treatment of Parkinson’s Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD). Objective To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD. Design, Setting, and Participants This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson’s Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score. Intervention Bilateral STN-DBS for moderate to advanced PD. Main Outcomes and Measures Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs. Results A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P &amp;lt; .001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P &amp;lt; .001). Activities of daily living without medication as measured by UPDRS-II improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P &amp;lt; .001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P &amp;lt; .001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P &amp;lt; .001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P &amp;lt; .001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P &amp;lt; .001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study. Conclusions and Relevance Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.
Global consensus statement on the management of pregnancy in inflammatory bowel disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie D. , Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B.

Mayo Clinic

Gut | September 9, 2025 | Volume: 75 | Issue: 2 | Pages: 208-251

10.1136/gutjnl-2025-336402 | PMID 40876906 Get It

Background & aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Neutrophil-to-Lymphocyte Ratio as a Biomarker in Clinically Stable Chronic Obstructive Pulmonary Disease: SPIROMICS Cohort
HOESTEREY, DANIEL , Markovic, Daniela , Buhr, Russell G. , Tashkin, Donald P., Barr, R. Graham, Belperio, John A. , Bowler, Russell P. , Bleecker, Eugene R., Couper, David J., Cooper, Christopher B. , Han, MeiLan K., Hansel, Nadia N. , Hastie, Annette T. , Hoffman, Eric A. , Kanner, Richard E. , O’Neal, Wanda K. , Ortega, Victor E. , Paine, Robert, Shrivastav, Abhishek K., Wells, J. Michael , Woodruff, Prescott G. , Hoesterey, Daniel T , Buhr, Russell G , Bowler, Russell P , Doerschuk, Claire M , Drummond, M Bradley , Hastie, Annette T , Hoffman, Eric A , Huang, Yvonne J , Krishnan, Jerry A , Wells, J Michael , Curtis, Jeffrey L , O'Neal, Wanda K , Dang, Hong , Barr, R. Graham, Couper, David J., Criner, Gerard J. , Doerschuk, Claire M. , Dransfield, Mark T. , Drummond, Michael , Fawzy, Ashraf , Freeman, Christine M. , Han, MeiLan King , Kaner, Robert J. , Kim, Victor, Martínez, Fernando J. , Shrivastav, Abhishek K., Curtis, Jeffrey L. , Barjaktarević, Igor

Mayo Clinic

Annals of the American Thoracic Society | September 8, 2025 | Volume: 22 | Issue: 12 | Pages: 1881-1890

10.1513/annalsats.202412-1265oc | PMID 40920896 Get It

Abstract Rationale Inflammation is central to chronic obstructive pulmonary disease (COPD) pathogenesis but incompletely represented in COPD prognostic models. The neutrophil-to-lymphocyte ratio (NLR) is a readily available inflammatory biomarker. Objectives To explore the associations of NLR with smoking status, clinical features of COPD, and future adverse outcomes. Methods We analyzed NLR calculated from the complete blood count of participants who currently or formerly smoked (n = 2,624) and tobacco-naive control subjects (n = 187) in the SPIROMICS multicenter observational cohort study. We assessed the stability of NLR at 6 weeks and 1 year, the association with select blood biomarkers, and the impact of smoking on NLR and cell counts. We stratified participants by NLR quartiles to compare cross-sectional clinical features at enrollment, prospectively observed exacerbations at 1 year, and mortality during longitudinal follow up. Results Higher NLR quartiles were broadly associated with more severe clinical features of COPD. NLR values were repeatable at 6 weeks (intraclass correlation coefficient, 0.74) and 1 year (intraclass correlation coefficient, 0.62). The impact of smoking on NLR varied with the severity of airflow limitation, mediated by an interaction between smoking, forced expiratory volume in 1 second percent predicted, and neutrophil counts but not lymphocyte counts. The highest NLR quartile (&gt;3.11) was associated with an increased risk of exacerbation over 1 year (adjusted odds ratio, 1.51; 95% confidence interval, 1.18, 1.92) and increased risk of mortality (adjusted hazard ratio, 1.41; 95% confidence interval, 1.20, 1.66) compared with quartiles 1–3. Conclusions Elevated NLR in stable COPD is a widely available biomarker associated with increased risk for exacerbation and death. The impact of cigarette smoking on NLR varies with disease severity.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L., Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L., Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 28, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1125-1180

10.1111/apt.70290 | PMID 40874657 Get It

ABSTRACT Background & Aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High‐quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data‐driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla C. , Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

American Journal of Gastroenterology | August 27, 2025 | Volume: 121 | Issue: 1 | Pages: 31-79

10.14309/ajg.0000000000003651 | PMID 40862489 Get It

Introduction: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into 10 categories with 34 GRADE recommendations and 35 Consensus statements. Discussion: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.